OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

by · The Cerbat Gem

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO – Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 69,191 shares, an increase of 248.2% from the November 30th total of 19,869 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average daily volume of 200,019 shares, the short-interest ratio is presently 0.3 days. Based on an average daily volume of 200,019 shares, the short-interest ratio is presently 0.3 days. Currently, 0.3% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

OKYO has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a report on Wednesday, October 8th. B. Riley initiated coverage on OKYO Pharma in a research note on Monday, December 8th. They issued a “buy” rating and a $5.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of OKYO Pharma in a research report on Tuesday, September 23rd. Finally, Zacks Research upgraded shares of OKYO Pharma to a “hold” rating in a report on Tuesday, September 16th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $6.00.

Check Out Our Latest Stock Analysis on OKYO

OKYO Pharma Price Performance

Shares of NASDAQ:OKYO traded up $0.06 during midday trading on Thursday, reaching $2.12. The company had a trading volume of 21,415 shares, compared to its average volume of 142,311. OKYO Pharma has a 1-year low of $0.90 and a 1-year high of $3.35. The business’s 50 day moving average price is $2.21 and its 200 day moving average price is $2.37.

Institutional Investors Weigh In On OKYO Pharma

A hedge fund recently bought a new stake in OKYO Pharma stock. Citadel Advisors LLC bought a new stake in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 15,355 shares of the company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 2.97% of the company’s stock.

About OKYO Pharma

(Get Free Report)

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.

Read More